Page last updated: 2024-12-06

lercanidipine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Lercanidipine is a dihydropyridine calcium channel blocker that is used to treat hypertension. It is synthesized by a multi-step process involving the reaction of an appropriately substituted pyridine with a dihydropyridine derivative. Lercanidipine selectively blocks the influx of calcium ions into vascular smooth muscle cells, resulting in vasodilation and a decrease in blood pressure. Its long-acting nature makes it suitable for once-daily dosing. Lercanidipine has been studied extensively for its potential benefits in treating hypertension, and its efficacy and safety have been demonstrated in multiple clinical trials. The compound is also being investigated for its potential therapeutic effects in other cardiovascular conditions, such as angina pectoris and heart failure.'

Cross-References

ID SourceID
PubMed CID65866
CHEMBL ID250270
CHEBI ID135930
SCHEMBL ID25268
SCHEMBL ID6846222
MeSH IDM0167715

Synonyms (52)

Synonym
AC-15409
AKOS005571238
lercanidipine [inn]
(+-)-2-((3,3-diphenylpropyl)methylamino)-1,1-dimethylethyl methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate
lercanidipine
DB00528
CHEBI:135930
NCGC00167492-02
CHEMBL250270
lercanil
5-o-[1-[3,3-diphenylpropyl(methyl)amino]-2-methylpropan-2-yl] 3-o-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
lercanidipine (inn)
D08111
lercanil (tn)
100427-26-7
STK639861
1-[(3,3-diphenylpropyl)(methyl)amino]-2-methylpropan-2-yl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
A800200
o5-[1-[3,3-diphenylpropyl(methyl)amino]-2-methyl-propan-2-yl] o3-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid o5-[1-[3,3-diphenylpropyl(methyl)amino]-2-methylpropan-2-yl] ester o3-methyl ester
3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(3,3-diphenylpropyl)methylamino)-1,1-dimethylethyl methyl ester
v7xtj4r0bh ,
unii-v7xtj4r0bh
lercanidipine [inn:ban]
masnidipine
FT-0631006
S5861
ZDXUKAKRHYTAKV-UHFFFAOYSA-N
lercanidipine [mi]
lercanidipine [who-dd]
3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-((3,3-diphenylpropyl)methylamino)-1,1-dimethylethyl methyl ester
2-((3,3-diphenylpropyl)methylamino)-1,1-dimethylethyl methyl (4rs)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
HY-B0612
BBL029074
SCHEMBL25268
SCHEMBL6846222
DTXSID2048327
HMS3604G05
3-{1-[(3,3-diphenylpropyl)(methyl)amino]-2-methylpropan-2-yl} 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
sr-01000884000
SR-01000884000-1
[2-oxo-3-(3-trifluoromethyl-phenoxy)-propyl]-phosphonic
3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3-[2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl] 5-methyl ester
3-(1-((3,3-diphenylpropyl)(methyl)amino)-2-methylpropan-2-yl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
BCP21318
AS-75252
Q410492
SDCCGSBI-0633690.P001
NCGC00167492-11
C13971
A929939
EN300-19767833

Research Excerpts

Overview

Lercanidipine (LRD) is a long-acting antihypertensive calcium channel blocker with anti-inflammatory, anti-apoptotic, and antioxidant effects. It is a third-generation dihydropyridine (DHP) blocker of calcium channels.

ExcerptReferenceRelevance
"Lercanidipine (LRD) is a long-acting antihypertensive calcium channel blocker with anti-inflammatory, anti-apoptotic, and antioxidant effects."( Lercanidipine alleviates doxorubicin-induced lung injury by regulating PERK/CHOP and Bax/Bcl 2/Cyt c pathways.
Gül, S; Hüseynov, İ; Milletsever, A; Selçuk, E; Selli, J; Tepebaşı, MY, 2023
)
3.07
"Lercanidipine is a third-generation dihydropyridine (DHP) blocker of calcium channels, and as such it possesses unique qualities such as high lipophilicity and high vascular selectivity."( New Insights into the Nephroprotective Potential of Lercanidipine.
Franczyk, B; Fularski, P; Hajdys, J; Leszto, K; Majchrowicz, G; Młynarska, E; Rysz, J; Stabrawa, M, 2023
)
1.88
"Lercanidipine is a third-generation dihydropyridine with low rate of adverse events."( Lercanidipine-induced chylous ascites: Case report and literature review.
Alegre, F; Basualdo, JE; Fernández-Ros, N; Huerta, A; Landecho, MF; Lucena, JF; Morales, MI; Rosado, IA, 2017
)
2.62
"Lercanidipine is a calcium antagonist with no cardiodepressant activity, long lasting antihypertensive action and reno-protective effect. "( Lercanidipine and T-type calcium current.
Cerbai, E; Mugelli, A, 2018
)
3.37
"Lercanidipine hydrochloride is a calcium channel blocker used in the treatment of hypertension. "( Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride.
Ghodake, VN; Korabu, SS; Ranpise, NS, 2014
)
2.07
"Lercanidipine is a vasoselective dihydropyridine calcium antagonist, mainly used for the treatment of hypertension and angina pectoris. "( Development of fast dissolving oral films containing lercanidipine HCl nanoparticles in semicrystalline polymeric matrix for enhanced dissolution and ex vivo permeation.
Chonkar, AD; Dengale, S; Jain, P; Managuli, RS; Mutalik, S; Rao, JV; Udupa, N, 2016
)
2.13
"Lercanidipine is an effective antihypertensive drug in improving BPV."( Effects of lercanidipine hydrochloride versus felodipine sustained-release on day-to-day home blood pressure variability.
Dai, Q; Gong, J; Jin, H; Lu, X; Peng, J; Wang, B; Wang, H; Wu, Y; Xu, M; Xu, X; Yan, J; Zhang, M; Zhao, S, 2016
)
1.55
"Lercanidipine is a third-generation CCB with peculiar pharmaceutical properties."( Vascular effects of the lercanidipine/enalapril combination: clinical relevance.
Parati, G, 2016
)
1.46
"Lercanidipine is a lipophilic calcium channel blocker and a widely used antihypertensive agent. "( Lercanidipine-induced chyloperitoneum in patients on peritoneal dialysis.
Chen, HW; Huang, JW; Tsai, TJ; Wu, KD; Yang, WS,
)
3.02
"Lercanidipine is an effective dihydropyridine calcium channel blocker of the third generation characterized by a long half-life and its lipophylicity."( Patient adherence and the choice of antihypertensive drugs: focus on lercanidipine.
Burnier, M; Maillard, MP; Pruijm, MT, 2008
)
1.3
"Lercanidipine/enalapril is a promising example of a fixed-dose combination of these drug classes."( Rationale for the use of a fixed-dose combination in the management of hypertension: efficacy and tolerability of lercanidipine/enalapril.
Borghi, C; Cicero, AF, 2010
)
1.29
"Lercanidipine is a new vasoselective dihydropyridine calcium channel blocker with a short plasma half-life, long duration of action, and demonstrated cardioprotective properties. "( Effects of lercanidipine on coronary reactivity and myocardial remodeling in transition to heart failure in cardiomyopathic hamsters.
Dumont, L; Leonardi, A; Massicotte, J; Sironi, G; Viens, A; Wang, H; Yao, MH, 2003
)
2.15
"Lercanidipine is a calcium channel blockers of high efficacy and low incidence of adverse effects in the clinical settings of general practice. "( [Evaluation of lercanidipine in the general practice setting].
Aguilar, A; Angulo, E; Canelada, JA; Cidoncha, F; Díaz Olea, E; Fuentes, J; Garrido, J; Guerras, M; Hidalgo, P; Iglesias, M; Lapie, J; López Acedo, A; Peña, J; Robles, NR, 2003
)
2.11
"Lercanidipine (Zanidip) is a vasoselective dihydropyridine calcium channel antagonist that causes systemic vasodilation by blocking the influx of calcium ions through L-type calcium channels in cell membranes. "( Lercanidipine : a review of its efficacy in the management of hypertension.
Bang, LM; Chapman, TM; Goa, KL, 2003
)
3.2
"Lercanidipine is a highly lipophilic CCB with a specific safety profile linked to its pharmacokinetics."( [Efficacy and acceptability of lercanidipine are not age dependent in patients with essential hypertension: the AGATE study].
Bassous, M; Clerson, P; Goullard, L; Grès, CS; Poncelet, P; Ribstein, J, 2004
)
1.33
"Lercanidipine is a calcium channel blocker with antioxidant actions."( Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension.
Coelho, EB; Gerlach, RF; Lopes, LF; Martinez, ML; Nobre, F; Rocha, JB; Tanus-Santos, JE, 2006
)
2.5
"Lercanidipine is a new highly lipophylic dihydropyrdine derivative of the third generation with equal efficacy but an improved tolerability profile. "( [Lercanidipine, a third generation calcium antagonist. Which advantages?].
Burnier, M; Meier, P, 2006
)
2.69
"Lercanidipine is a lipophilic, dihydropyridine calcium antagonist with a long receptor half-life. "( Lercanidipine in hypertension.
Borghi, C, 2005
)
3.21
"Lercanidipine is a novel dihydropyridine (DHP) calcium-channel blocker indicated for the treatment of mild-to-moderate hypertension. "( Lercanidipine in the treatment of hypertension.
Beckey, C; Lundy, A; Lutfi, N, 2007
)
3.23
"Lercanidipine is an effective and well tolerated calcium channel blocker of the third generation. "( Efficacy and tolerability of lercanidipine in patients with hypertension: results of a Phase IV study in general practice.
Burnier, M; Gasser, UE, 2007
)
2.07
"Lercanidipine is a recently introduced example of a lipophilic and vasoselective dihydropyridine CA."( The pharmacological properties of lipophilic calcium antagonists.
van Zwieten, PA, 1998
)
1.02
"Lercanidipine (Zanidip) is a new calcium antagonist belonging to the dihydropyridine family suitable for the first-line treatment of hypertension. "( [Pharma-clinics. Drug of the month. Lercanidipine (Zanidip)].
Krzesinski, JM, 1999
)
2.02
"Lercanidipine (LER) is a recently introduced lipophilic calcium antagonist with no cardiodepressant activity and long-lasting antihypertensive action."( Electrophysiologic effects of lercanidipine on repolarizing potassium currents.
Cerbai, E; Davoli, G; DePaoli, P; DiCiolla, F; Lisi, G; Maccherini, M; Matucci, R; Mugelli, A; Sani, G; Sartiani, L, 2000
)
1.32
"Lercanidipine is a vasoselective dihydropyridine calcium antagonist which causes systemic vasodilation by blocking the influx of calcium ions through L-type calcium channels in cell membranes. "( Lercanidipine: a review of its use in hypertension.
Jarvis, B; McClellan, KJ, 2000
)
3.19
"Lercanidipine is an effective and well tolerated once daily antihypertensive agent in patients with mild to moderate hypertension. "( Lercanidipine: a review of its use in hypertension.
Jarvis, B; McClellan, KJ, 2000
)
3.19
"Lercanidipine is a novel DHP CCB effective for the treatment of mild-to-moderate hypertension."( Lercanidipine: a novel dihydropyridine calcium-channel blocker.
Epstein, M,
)
2.3

Effects

Lercanidipine has been shown to be effective in a wide range of hypertensive patients, including mild-to-moderate hypertension, severe hypertension, the elderly, and those with isolated systolic hypertension. The drug has one of the highest measured tolerances to cholesterol.

ExcerptReferenceRelevance
"Lercanidipine has also shown efficacy similar to that of other antihypertensives, including atenolol, captopril, and losartan."( Lercanidipine in the treatment of hypertension.
Beckey, C; Lundy, A; Lutfi, N, 2007
)
2.5
"Lercanidipine has now been shown to have one of the highest measured tolerances to cholesterol, which may indicate its ability to treat a broad range of hypertensive patients with varying degrees of progressive atherosclerotic disease."( Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties.
Herbette, LG; Leonardi, A; Sartani, A; Vecchiarelli, M, 1998
)
2.46
"Lercanidipine has been shown to be effective in a wide range of hypertensive patients, including mild-to-moderate hypertension, severe hypertension, the elderly, and those with isolated systolic hypertension."( Lercanidipine: a novel dihydropyridine calcium-channel blocker.
Epstein, M,
)
2.3

Treatment

Lercanidipine was introduced at a dose of 10 mg and titration to 20 mg was optional according to the physician's decision. Treatment with lercanIDipine promotes nephroprotection, reduction of left ventricular hypertrophy, improvement of elastic properties of blood vessels and reduction of central pressure.

ExcerptReferenceRelevance
"Lercanidipine treatment also significantly (P<0.05) reduced blood levels of the endogenous NOS inhibitor asymmetric dimethylarginine."( Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers.
Agrawal, R; Bahlmann, FH; Bode-Böger, SM; Fliser, D; Haller, H; Kielstein, JT; Kirsch, T; Lindschau, C; Marx, A; Meier, M; Menne, J; Muller, D; Park, JK, 2006
)
1.06
"In lercanidipine-treated animals a significant and dose-dependent effect on intimal hyperplasia was observed."( Effect of lercanidipine and its (R)-enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbits.
Baetta, R; Barberi, L; Catapano, AL; Comparato, C; Donetti, E; Farina, P; Leonardi, A; Natali, M; Soma, MR, 1998
)
1.22
"Lercanidipine treatment was suspended in one patient because of epigastric pain."( Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension.
Barbagallo Sangiorgi, G; Barbagallo, M, 2000
)
1.32
"Treatment with lercanidipine/enalapril in fixed combination was associated with a reduction in both SBP and DBP already at 1 month; this reduction was sustained until month 2 (SBP: 131 ± 7 mmHg; DBP: 79 ± 5 mmHg; p < 0.05 vs baseline)."( Efficacy and safety of lercanidipine/enalapril fixed combination in Lebanon: a prospective observational study.
Arnaout, S, 2015
)
1.07
"Treatment with lercanidipine and felodipine both resulted in reduction of BPV and HRV. "( Effects of lercanidipine hydrochloride versus felodipine sustained-release on day-to-day home blood pressure variability.
Dai, Q; Gong, J; Jin, H; Lu, X; Peng, J; Wang, B; Wang, H; Wu, Y; Xu, M; Xu, X; Yan, J; Zhang, M; Zhao, S, 2016
)
1.18
"Treatment with lercanidipine promotes nephroprotection, reduction of left ventricular hypertrophy, improvement of elastic properties of blood vessels and reduction of central pressure."( [Lercanidipine in the treatment of arterial hypertension].
Iosava, IK; Minushkina, LO, 2012
)
1.63
"Treatment with lercanidipine countered vascular changes primarily in small-sized coronary arteries."( Effect of treatment with lercanidipine on heart of Cohen-Rosenthal diabetic hypertensive rats.
Amenta, F; Peleg, E; Rosenthal, T; Sabbatini, M; Tomassoni, D, 2003
)
0.96
"Treatment with lercanidipine was introduced at a dose of 10 mg and titration to 20 mg was optional according to the physician's decision."( Efficacy and tolerability of lercanidipine in patients with hypertension: results of a Phase IV study in general practice.
Burnier, M; Gasser, UE, 2007
)
0.97
"Treatment with lercanidipine and Leucoselect restored, at least in part, responses to noradrenaline, acetylcholine and iloprost without affecting those to L-NAME and sodium nitroprusside."( Gender differences and antioxidant treatment affect aortic reactivity in short-term diabetic rats.
Bolego, C; Cignarella, A; Pinna, C; Puglisi, L; Zanardo, R, 2001
)
0.65

Toxicity

A fixed-dose combination (FDC) of enalapril and lercanidipine has been shown to be effective and safe in reducing blood pressure. The study was collected in an overall limited number of patients in a single center.

ExcerptReferenceRelevance
"A fixed-dose combination (FDC) of enalapril and lercanidipine has been shown to be effective and safe in reducing blood pressure in randomized clinical trials."( Efficacy and safety of a fixed-dose combination of lercanidipine and enalapril in daily practice. A comparison of office, self-measured and ambulatory blood pressure.
Bramlage, P; Kreutz, R; Scholze, J; Trenkwalder, P, 2011
)
0.88
" Treatment was associated with a low incidence of adverse events (3."( Efficacy and safety of a fixed-dose combination of lercanidipine and enalapril in daily practice. A comparison of office, self-measured and ambulatory blood pressure.
Bramlage, P; Kreutz, R; Scholze, J; Trenkwalder, P, 2011
)
0.62
" Adverse effects were seen in only one patient (0."( Efficacy and safety of a lercanidipine/enalapril fixed-dose combination in hypertensive patients in Portugal.
Maldonado, J; Pereira, T; Tavares, A, 2014
)
0.71
" The treatment efficacy and the incidence of adverse events were evaluated at the end of 4, 8 and 12 weeks after treatment initiation."( Efficacy and safety evaluation of perindopril-lercanidipine combined therapy in patients with mild essential hypertension.
Yang, Z, 2015
)
0.68
" Four adverse events were observed in group A, while seven and nineteen adverse events occurred in group B and in group C, respectively."( Efficacy and safety evaluation of perindopril-lercanidipine combined therapy in patients with mild essential hypertension.
Yang, Z, 2015
)
0.68
"Although its results were collected in an overall limited number of patients in a single center, this study shows that the combination of perindopril and lercanidipine, compared with lercanidipine alone or perindopril alone, was effective in improving blood pressure in mild essential hypertensive patients, and also decreased the incidence of adverse events."( Efficacy and safety evaluation of perindopril-lercanidipine combined therapy in patients with mild essential hypertension.
Yang, Z, 2015
)
0.87
" No other adverse effects were reported."( Efficacy and safety of lercanidipine/enalapril fixed combination in Lebanon: a prospective observational study.
Arnaout, S, 2015
)
0.73
" For evaluation of the safety profile, the frequencies of adverse events between groups were also not significantly different."( Evaluation of the Efficacy and Safety of the Lercanidipine/Valsartan Combination in Korean Patients With Essential Hypertension Not Adequately Controlled With Lercanidipine Monotherapy: A Randomized, Multicenter, Parallel Design, Phase III Clinical Trial.
Ahn, JC; Ahn, T; Cha, DH; Cho, JH; Cho, SW; Choi, DJ; Hong Baek, S; Hong, S; Hong, TJ; Jeon, ES; Jeon, HK; Jeong, JO; Jeong, MH; John, SH; Juhn, JH; Kang, JH; Kim, BS; Kim, DW; Kim, JJ; Kim, MH; Kim, NH; Kim, SK; Kim, SW; Kim, SY; Kim, YN; Kwan, J; Lee, HY; Lee, NH; Lee, SH; Lee, SY; Lee, YJ; Na, SH; Oh, BH; Park, CG; Park, SH; Park, WJ; Rhee, MY; Ryu, JK; Shin, ES; Shin, JH; Uk Lee, S; Won, KH; Yoo, SY, 2015
)
0.68
" We report a serious side effect of ibrutinib potentially attributable to interaction with the moderate CYP3A4 inhibitor verapamil."( Adverse event potentially due to an interaction between ibrutinib and verapamil: a case report.
Bilbault, P; Gourieux, B; Lambert Kuhn, E; Levêque, D; Lioure, B, 2016
)
0.43
"This is the first description of a serious side effect of ibrutinib likely due to an interaction with the CYP3A4 inhibitor verapamil."( Adverse event potentially due to an interaction between ibrutinib and verapamil: a case report.
Bilbault, P; Gourieux, B; Lambert Kuhn, E; Levêque, D; Lioure, B, 2016
)
0.43

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic profile of calcium antagonists, although influenced to some degree by interactions with their target calcium-channel receptor, appears to be largely dictated by their interactions with cell membranes at the molecular level."( Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties.
Herbette, LG; Leonardi, A; Sartani, A; Vecchiarelli, M, 1998
)
1.74
" The present study describes the enantioselective pharmacokinetic interaction between LER and FV in healthy volunteers."( Enantioselectivity in the pharmacokinetic interaction between fluvastatin and lercanidipine in healthy volunteers.
Boralli, VB; Coelho, EB; Lanchote, VL; Marques, MP; Sampaio, SA, 2009
)
0.58

Bioavailability

The dissolution and oral bioavailability of lercanidipine was significantly increased by addition of surfactants. These findings suggest that nanoproliposomes are promising carriers in improving the oral bio availability and bioactivity of l exercise. The study was aimed at the development of gastroretentive floating pulsatile release tablets (FPRTs) to enhance bioavailability and treat early morning surge in blood pressure.

ExcerptReferenceRelevance
" In order to estimate the relative enhancement in bioavailability one optimized formulation was evaluated in rabbits."( Development and evaluation of buccoadhesive controlled release tablets of lercanidipine.
Charde, S; Kumar, L; Mudgal, M; Saha, R, 2008
)
0.58
"The present study deals with the development and characterization of self-nanoemulsifying drug delivery system (SNEDDS) to improve the oral bioavailability of poorly soluble third generation calcium channel blocker lercanidipine (LER)."( Study of cosurfactant effect on nanoemulsifying area and development of lercanidipine loaded (SNEDDS) self nanoemulsifying drug delivery system.
Amin, S; Kohli, K; Parmar, N; Singla, N, 2011
)
0.79
"2% (w/v) sodium lauryl sulphate (SLS), and in vivo bioavailability in rabbits."( Formulation and evaluation of bilayered gastroretentable mucoadhesive patch for stomach-specific drug delivery.
Jirwankar, P; Mehta, S; Pandey, S; Pandit, S; Patil, A; Tripathi, P, 2013
)
0.39
" It is a poor water soluble drug with absolute bioavailability of 10%."( Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride.
Ghodake, VN; Korabu, SS; Ranpise, NS, 2014
)
0.63
" The dissolution and oral bioavailability of lercanidipine was significantly increased by addition of surfactants."( Dissolution and bioavailability of lercanidipine-hydroxypropylmethyl cellulose nanoparticles with surfactant.
Baek, IH; Cho, W; Choo, GH; Ha, ES; Hwang, SJ; Jin, SE; Jung, YS; Kim, JS; Kim, MS, 2015
)
0.95
"The present study was aimed at the development of gastroretentive floating pulsatile release tablets (FPRTs) of lercanidipine HCl to enhance the bioavailability and treat early morning surge in blood pressure."( Gastroretentive pulsatile release tablets of lercanidipine HCl: development, statistical optimization, and in vitro and in vivo evaluation.
Deshpande, PB; Mutalik, S; Nayak, UY; Reddy, GS, 2014
)
0.87
" However, it suffers from food dependent absorption, poor solubility, low permeability and considerable first pass metabolism, resulting in highly variable and low bioavailability of 10%."( Development of fast dissolving oral films containing lercanidipine HCl nanoparticles in semicrystalline polymeric matrix for enhanced dissolution and ex vivo permeation.
Chonkar, AD; Dengale, S; Jain, P; Managuli, RS; Mutalik, S; Rao, JV; Udupa, N, 2016
)
0.68
" The in-situ studies showed a significant increase in absorption rate across the rat intestinal membrane."( A novel nanoproliposomes of lercanidipine: Development, in vitro and preclinical studies to support its effectiveness in hypertension therapy.
Arumugam, K; Averineni, RK; Deshpande, A; Deshpande, PB; Gurram, AK; Musmade, P; Mutalik, S; Reddy, MS; Shavi, GV; Udupa, N, 2016
)
0.73
"These findings suggest that nanoproliposomes are promising carriers in improving the oral bioavailability and bioactivity of lercanidipine, and can be an effective therapy in the management of hypertension."( A novel nanoproliposomes of lercanidipine: Development, in vitro and preclinical studies to support its effectiveness in hypertension therapy.
Arumugam, K; Averineni, RK; Deshpande, A; Deshpande, PB; Gurram, AK; Musmade, P; Mutalik, S; Reddy, MS; Shavi, GV; Udupa, N, 2016
)
0.93

Dosage Studied

An 80-year-old white female with hypertension treated with lercanidipine developed chylous ascites and abdominal pain after the dosage of the CCB was doubled. Two simple, accurate, precise and fully validated analytical methods for the simultaneous determination of enalapril + enalapil in combined dosage forms have been developed.

ExcerptRelevanceReference
" In the dose-response study, dP/dtmax was practically not affected."( Haemodynamic effects of lercanidipine in anaesthetized open-chest dogs.
Greto, L; Leonardi, A; Montagna, E; Sironi, G; Testa, R, 1996
)
0.6
" The reduction in 24 h blood pressure with 5 mg lercanidipine (6+/-7/4+/-5 mmHg) was significantly greater compared with placebo for diastolic pressure only, and when hourly average blood pressure changes were considered, this reduction did not extend to the final hours of the dosing interval."( Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. Multicenter Study Investigators.
Omboni, S; Zanchetti, A, 1998
)
0.85
" Ambulatory blood pressure monitoring showed that the antihypertensive effects of both drugs lasted for the full 24-h dosing period and followed a circadian pattern."( Lercanidipine vs lacidipine in isolated systolic hypertension.
Greenough, A; McDonald, C; Millar-Craig, M; Mitchell, L; Shaffu, B, 2003
)
1.76
"8-fold difference in IC(50), but the slope of the dose-response curve was much steeper (n(H)=2."( Molecular mechanisms of vasoselectivity of the 1,4-dihydropyridine lercanidipine.
Herzig, S; Wirtz, S, 2004
)
0.56
" Two simple, accurate, precise and fully validated analytical methods for the simultaneous determination of enalapril and lercanidipine in combined dosage forms have been developed."( Determination of pK(a) values of some antihypertensive drugs by liquid chromatography and simultaneous assay of lercanidipine and enalapril in their binary mixtures.
Gumustas, M; Ozkan, SA; Sanli, N; Sanlı, S, 2010
)
0.78
" After constructing the dose-response curve using 0 (vehicle-treated control), 1/16, 1/8, 1/4, 1/2 and 1 doses, all possible combinations of both drugs were tested."( Drug synergism of antihypertensive action in combination of telmisartan with lercanidipine in spontaneous hypertensive rats.
Kim, IS; Kim, Y; Lee, JJ; Lee, KH; Myung, CS; Park, HJ; Shin, CY; Zhang, WY, 2010
)
0.59
" The Marketing Authorisation Holder should clarify the dosing instructions in relation to meals and identify a sufficient time-lapse to ensure an exposure similar to that obtained in phase III clinical efficacy studies."( Differences in lercanidipine systemic exposure when administered according to labelling: in fasting state and 15 minutes before food intake.
Álvarez, C; Frías, J; García-Arieta, A; Gómez, E; Govantes, C; Guerra, P; Simón, M, 2012
)
0.73
" All of them were treated orally with lercanidipine at a single daily fixed dosage of 10mg for 28 consecutive days and the genotypes of the MTHFR C677T polymorphism were determined."( Polymorphism of the methylenetetrahydrofolate reductase gene C677T and its influence on the antihypertensive and vascular protective effects of short-term lercanidipine treatment.
Huang, J; Luo, M; Shen, Y; Xu, H; Zheng, H, 2012
)
0.85
" At 4 weeks, the dosage of Benazepril was titrated up to 20 mg if the diastolic blood pressure (DBP) remained ≥ 90 mmHg."( Efficacy and safety of the treatment: combination of benazepril/lercanidipine vs. benazepril alone in patients with mild-to-moderate hypertension.
An, WS; Chen, GH; Chen, T; Li, JD; Yang, TS; Zhang, XX; Zhong, ZY, 2013
)
0.63
" This pooled analysis investigates the dose-response relationship of fixed-dose lercanidipine + enalapril in patients with mild-to-moderate hypertension."( Dose-response effect of the lercanidipine/enalapril combination: a pooled analysis.
Rizzoni, D, 2016
)
0.96
"This pooled analysis of four randomized studies shows evidence of a dose-response effect in BP reduction with different fixed combinations of lercanidipine + enalapril."( Dose-response effect of the lercanidipine/enalapril combination: a pooled analysis.
Rizzoni, D, 2016
)
0.93
"An 80-year-old white female with hypertension treated with lercanidipine, developed chylous ascites and abdominal pain after the dosage of the CCB was doubled."( Lercanidipine-induced chylous ascites: Case report and literature review.
Alegre, F; Basualdo, JE; Fernández-Ros, N; Huerta, A; Landecho, MF; Lucena, JF; Morales, MI; Rosado, IA, 2017
)
2.14
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
diarylmethaneAny compound containing two aryl groups connected by a single C atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
phosphopantetheinyl transferaseBacillus subtilisPotency63.09570.141337.9142100.0000AID1490
ATAD5 protein, partialHomo sapiens (human)Potency23.71490.004110.890331.5287AID493106; AID493107
Fumarate hydrataseHomo sapiens (human)Potency35.48130.00308.794948.0869AID1347053
USP1 protein, partialHomo sapiens (human)Potency27.33420.031637.5844354.8130AID504865
polyproteinZika virusPotency35.48130.00308.794948.0869AID1347053
arylsulfatase AHomo sapiens (human)Potency0.12001.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency20.69780.035520.977089.1251AID504332
chromobox protein homolog 1Homo sapiens (human)Potency25.11890.006026.168889.1251AID488953
flap endonuclease 1Homo sapiens (human)Potency0.15000.133725.412989.1251AID588795
ras-related protein Rab-9AHomo sapiens (human)Potency58.04790.00022.621531.4954AID485297
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency21.36390.00378.618923.2809AID2660; AID2667; AID2668
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency17.48820.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency11.88560.004611.374133.4983AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency22.79360.005612.367736.1254AID624032
M-phase phosphoprotein 8Homo sapiens (human)Potency37.68580.177824.735279.4328AID488949
D(1A) dopamine receptorSus scrofa (pig)Potency26.12160.00378.108123.2809AID2667
Ataxin-2Homo sapiens (human)Potency19.95260.011912.222168.7989AID588378
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (37)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1808022Inhibition of porcine heart malate dehydrogenase assessed as critical aggregation concentration preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec by spectrophotometric method2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID1808020Inhibition of porcine heart malate dehydrogenase preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec by spectrophotometric method2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID537135Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi infected in rhesus monkey LLC-MK2 cells after 48 hrs by MTT assay2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID537136Cytotoxicity against rhesus monkey LLC-MK2 cells after 48 hrs by MTT assay2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID537137Selectivity index, ratio of IC50 for rhesus monkey LLC-MK2 cells to IC50 for amastigotes of Leishmania chagasi MHOM/BR/1972/LD2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID640615Clearance in human liver microsomes at 1 uM measured after 60 mins by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.
AID1678479Inhibition of recombinant His6-tagged SARS-CoV-2 main protease using Dabcyl-KTSAVLQ-SGFRKM-E(Edans-NH2) as substrate preincubated for 15 mins followed by substrate addition by FRET based assay2020ACS medicinal chemistry letters, Dec-10, Volume: 11, Issue:12
Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2.
AID537133Antileishmanial activity against promastigotes of Leishmania major MHOM/1L/80/Fredlin after 18 hrs by MTT assay2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID1678478Inhibition of recombinant His6-tagged SARS-CoV-2 main protease assessed as residual enzyme activity at 100 uM using Dabcyl-KTSAVLQ-SGFRKM-E(Edans-NH2) as substrate preincubated for 15 mins followed by substrate addition by FRET based assay relative to con2020ACS medicinal chemistry letters, Dec-10, Volume: 11, Issue:12
Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2.
AID1808021Inhibition of porcine heart malate dehydrogenase assessed as reduction in enzyme inhibition at 3 times IC50 preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec in presence of 0.01% Triton-X100 by spectrop2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID537138Selectivity index, ratio of IC50 for rhesus monkey LLC-MK2 cells to IC50 for trypomastigotes of Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID537131Antileishmanial activity against amastigotes of Leishmania chagasi MHOM/BR/1972/LD after 24 hrs by MTT assay2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID537139Cytotoxicity in BALB/c mouse erythrocytes assessed as hemolysis at 50 uM after 3 hrs2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID537132Antileishmanial activity against promastigotes of Leishmania amazonensis WHO/BR/00/LT0016 after 18 hrs by MTT assay2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID537134Antileishmanial activity against promastigotes of Leishmania braziliensis MHO/BR/75/M2903 after 18 hrs by MTT assay2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID311932Inhibition of ASM in human H4 cells assessed as residual activity at 10 uM2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID1808019Inhibition of SARS CoV2 C-terminal His6-tagged 3CL protease (3264 to 3569 residues) expressed in Escherichia coli BL21 DE3 using rr-K(MCA)-ATLQAIAS-K(DNP)-COOH preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 0.02021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID537130Antileishmanial activity against promastigotes of Leishmania chagasi MHOM/BR/1972/LD after 18 hrs by MTT assay2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (249)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's12 (4.82)18.2507
2000's105 (42.17)29.6817
2010's108 (43.37)24.3611
2020's24 (9.64)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 95.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index95.53 (24.57)
Research Supply Index5.81 (2.92)
Research Growth Index5.13 (4.65)
Search Engine Demand Index171.38 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (95.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials68 (25.56%)5.53%
Reviews38 (14.29%)6.00%
Case Studies20 (7.52%)4.05%
Observational3 (1.13%)0.25%
Other137 (51.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (12)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effects of Intensive Vasodilating add-on Therapy on Peripheral Vascular Resistance and Coronary Flow Reserve in Patients With Essential Hypertension [NCT01180413]Phase 448 participants (Actual)Interventional2010-12-31Completed
Treatment of Essential Hypertension With Vasodip-Combo 20. Efficacy and Safety Evaluation With 24 h Ambulatory Blood Pressure Measurements [NCT01211314]Phase 410 participants (Actual)Interventional2011-01-31Terminated(stopped due to sponsor decision)
A Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy Phase II Trial to Evaluate the Efficacy and Safety of the Combinations of Lercanidipine and Valsartan in Comparison to Each Component Administered Alone and to Determine the Optimal Dos [NCT01122251]Phase 2441 participants (Anticipated)Interventional2009-12-31Completed
The Efficacy of Renal Artery Stent Combined With Standardized Medical Therapy in Patients With Atherosclerotic Renal Artery Stenosis [NCT02594410]Phase 4149 participants (Actual)Interventional2011-09-30Completed
Randomized, Parallel Group, Double-blind Trial to Evaluate Different Dose Combinations of Lercanidipine and Enalapril in Comparison With Each Component Administered Alone and With Placebo in Patients With Essential Hypertension [NCT01093807]Phase 21,039 participants (Actual)Interventional2010-03-31Completed
Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment [NCT00741585]Phase 421,983 participants (Actual)Interventional2008-09-01Completed
Effects of Antihypertensive Treatment on Cardiac Remodelling and Metabolic Profile in HIV Infected Patients: Randomized Longitudinal Study With Candesartan Versus Lercanidipine [NCT00564057]Phase 430 participants (Anticipated)Interventional2007-09-30Recruiting
A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel, Dose-Titration Study to Assess the Efficacy of Lercanidipine 10 mg and 20 mg Once Daily p. o. in Hypertensive Subjects (I or II WHO) With Elevated Body Weight. [NCT00160498]180 participants Interventional2004-05-31Completed
Intensive Non-Sympathetic Activating Vasodilatory Treatment in Hypertensive Patients With Microvascular Angina Pectoris [NCT00424801]10 participants (Actual)Interventional2007-01-31Terminated(stopped due to Due to recent findings relating MRI contrast to nephrogenic systemic fibrosis)
Bariatric Surgery and Pharmacokinetics Lercanidipine: BAR-MEDS Lercanidipine [NCT03497156]12 participants (Anticipated)Observational2016-11-02Recruiting
A Randomized, Multicenter, Parallel Design Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients Who Are Not Adequately Controlled on Lercanidipine 10mg Monotherapy. [NCT01928628]Phase 3449 participants (Actual)Interventional2012-05-31Completed
Effect of Renin-angiotensin-system (RAS) Blocker Drugs on Chronic Kidney Disease (CKD) Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01) [NCT03195023]Phase 4106 participants (Anticipated)Interventional2015-06-30Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]